Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evotec, Memphasys, MorphoSys - Growth Industry Health

Mario Hose Mario Hose, news.financial
0 Comments| January 20, 2020

{{labelSign}}  Favorites
{{errorMessage}}

He who is healthy has many desires, he who is ill only one. Companies around the globe deal with diseases and special features of nature in order to treat or cure them. In addition to the widespread disease of cancer, there are also topics that are less talked about, but are also a big market. Developments can be of great importance for investors, physicians and the people affected. It can therefore be worthwhile to deal with the variety of topics.


Expert for drug discovery

Evotec (FSE: EVT) claims to be one of the leading suppliers in the field of active ingredient research, drawing on the know-how accumulated over more than two decades. The company has its headquarters in Hamburg and employs more than 2,900 people worldwide. With a share price of EUR 24.65, Evotec's market capitalization is more than EUR 3.6 billion, making it one of the larger companies in the industry.


Innovations in fertility

Memphasys (ASX: MEM) from Australia is still in the early stages of its corporate development and is working on the topic of artificial insemination to offer couples who wish to have children an improved chance of success for a successful pregnancy. The company's product is called FELIX and is currently in the test phase. A major market launch is scheduled for the second half of 2020. The value of the company on the stock exchange currently amounts to EUR 26 million and a successful operative development should have a corresponding impact.


Experience with antibody technologies

With a share price of EUR 118.70, MorphoSys (FSE: MOR) has a market capitalization of EUR 3.8 billion. According to MorphoSys, it has made a name for itself in the pharmaceutical industry with its antibody technologies. The company develops both its own active ingredients and those of its partners. In drug discovery and development, the Company relies primarily on its innovative technologies. Together with its partners, MorphoSys has built a drug pipeline with more than 100 fully human antibody candidates.


CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our ´Conflict of Interest & Risk Disclosure´.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company